secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2026-08-04T11:02:43+00:00
Accession:  0000078003-26-000094
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q2 2026: Revenue $15.0B, raises FY guidance midpoint by $500M, reports net loss on $4.3B impairments
--------------------------------------------------------------------------------

- Q2 revenue $15.0B (+1% operational); launched/acquired products grew 18% operationally.
- Reported net loss $248M ($0.04 LPS) from $4.3B impairments; adjusted EPS $0.77 flat YoY.
- Raises FY2026 revenue guidance to $60.5-$62.5B (midpoint +$500M); reaffirms adjusted EPS $2.80-$3.00.
- Announces additional $2.5B in productivity savings from 2027-2029; ongoing cost realignment program.
- Pipeline: Lorbrena 7-yr PFS HR 0.19, Padcev MIBC approval, Litfulo vitiligo Phase 3 positive, sigvotatug vedotin miss.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/0000078003-26-000094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-20260804.htm
  HTML page:      https://secwatch.observer/filing/0000078003-26-000094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer